A Phase 1, Randomized Study to Evaluate the Safety and Immunogenicity of VBI-2901a, a Trivalent Coronavirus Vaccine Candidate in Healthy Adults Previously Vaccinated With Licensed COVID-19 Vaccines
Latest Information Update: 21 Nov 2023
At a glance
- Drugs VBI 2901 (Primary) ; Aluminium phosphate
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors VBI Vaccines
Most Recent Events
- 14 Nov 2023 According to VBI Vaccines media release, additional durability and breadth data from the Phase 1 study is expected in Q1 2024.
- 27 Sep 2023 Interim results from this study presented in the VBI Vaccines media release.
- 14 Aug 2023 According to VBI Vaccines media release, interim data readout from this study expected.